A2 is dedicated to pushing the boundaries of science to transform medicine and turn the tide on cancer. We are focused on the next frontier in cell therapy: solid tumors. A2 engineers T cells that target the loss of genetic material in tumors, enabling the selective killing of tumor cells while leaving normal cells unharmed. The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang and has raised $136M since inception. Our investors include The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents) and Hartford HealthCare Endowment.

We have always walked our own path, at Alector. That’s what led us to the bold thinking and fresh, new approach of empowering the body’s immune system to fight disease. Join us in our mission to eliminate neurodegeneration and cancer through immuno-neurology and immuno-oncology. We are developing a broad portfolio of programs, currently in various stages of clinical trials. Alector is based in South San Francisco, CA. We were founded in 2013 by thought leaders in biotechnology, neuroscience, and antibody drug discovery.

AltPep Corp is a biomedical startup with a breakthrough approach for diagnosing and treating some of the world’s most intractable diseases: amyloid diseases.

Arbor Biotechnologies is an operator of a bio-discovery company intended to provide human diagnostic development services. The company's platform employs a diverse set of technologies and techniques including artificial intelligence, genome sequencing, gene synthesis, and high-throughput screening, enabling drug developers to accelerate the discovery of proteins for improving human health and sustainability.

Arc is a venture-backed startup manufacturing and selling high-performance electric boats. We’re starting with watersport boats, but have an eye toward electrifying the watercraft industry.

Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical needs, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson's disease (PD) and extending across the brain and affected organs.

Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve. CNS drug development has long suffered from limited innovation and high failure rates, especially for drugs that strive to modify the underlying cause of disease. Developing successful therapies requires several factors, including a deep knowledge of underlying disease mechanisms, exceptional chemistry, insights into viable translational models and strategies to match the right patients to the most effective drugs. We have brought these elements together at Autobahn to make a real difference in the lives of people.

Avitide, a Repligen Company, discovers, develops, manufactures and supplies custom and catalog biopharmaceutical affinity purification solutions to the biopharmaceutical industry. Avitide’s proprietary AVIPure™ affinity ligand portfolio sets the standard for precise affinity separations and consistent robust performance for its high-valued chromatographic products. Avitide develops these technologies with an industry-leading 3-month, concept to resin delivery service timeline that enables industry biopharmaceutical manufacturers and contract developers to achieve faster bioprocess development timelines, improved process economics, predictable scalability, and enable next-generation integrated continuous downstream processing.

Rather than ending with a time and a place, those conversations ended with hundreds of unrelated messages and a confused group of friends,” says Shaik. “Messaging wasn’t made for organizing hangouts, so we built a platform that was.” The app itself works something like a standalone version of Facebook Events, as it allows you to create an event with just a few taps, by filling out things like the event name, location, time, and description. To get started with the service, users sign up with their Facebook account information and then confirm their phone number via text.

BigHat is a developer of an AI-guided protein therapeutic platform used to integrate antibody characterization lab with machine learning technologies to engineer molecules with more complex functions and better biophysical properties. The company is applying these design capabilities to develop new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases.

BloomAPI strive to democratize access to healthcare data. To unlock a future where all EMRs are interoperable and where vendors can't hold data hostage for their competitive advantage. They are helping to make healthcare technology easier by connecting patients, providers, and payers.

Brightloom is a restaurant technology company that provides end-to-end, cloud-based software as a service platform that weaves digital solutions into the entire guest experience. Brightloom’s configurable technology suite combines convenience (digital ordering channels), personal connection (personalized marketing), and engagement (loyalty) for restaurant brands in today’s new digital era. Brightloom was originally incubated as a technology-powered fast-casual restaurant concept.